Overview

Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma

Status:
Terminated
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research is to learn if the combination of Genasense (oblimersen), carboplatin, and paclitaxel (GCP) can help to control metastatic uveal melanoma. The safety of this combination will also be studied.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Genta Incorporated
Treatments:
Albumin-Bound Paclitaxel
Carboplatin
Oblimersen
Paclitaxel